Unyango lweeSeli zeNS7CAR-T lubonisa isithembiso sokunyanga i-R/R T-ALL/LBL
Impapasho yakutshanje kwijenali iBlood inike ingqwalasela enkulu kumandla onyango lweeseli ze-NS7CAR-T ekunyangeni i-T-cell acute lymphoblastic leukemia (R/R T-ALL) ephinde yabuyela kwisimo sayo okanye enganyangekiyo (R/R T-ALL) kunye ne-T-cell lymphoblastic lymphoma (R/R T-LBL). Olu phononongo, olwenziwe njengovavanyo lweklinikhi lwesigaba soku-1 (ClinicalTrials.gov: NCT04572308), luvavanye ukhuseleko kunye nokusebenza kakuhle kolu nyango lutsha.
Uvavanyo luquke izigulane ezine-R/R T-ALL/LBL ezafumana iiseli ze-NS7CAR-T. Iziphumo zibonise ukuba unyango lwe-NS7CAR-T aluzange lukhuseleke nje kuphela kodwa lubonise nomsebenzi omangalisayo wokulwa nethumba. Izigulane ezinyangwe ngeeseli ze-NS7CAR-T zibonise iimpendulo ezibalulekileyo zeklinikhi, nto leyo ebonisa ukuba olu nyango lunamandla njengesixhobo esinamandla nxamnye nale mihlaza inzima.
Abaphandi abasemva kolu phando baquka iqela leengcali ezivela kwiSibhedlele iHebei Yanda Lu Daopei kunye neHebei Senlang Biotechnology Co., Ltd. Iziphumo zabo zibonisa ukuba iiseli ze-NS7CAR-T zinokuveliswa ngempumelelo ngaphandle kotshintsho olongezelelweyo lwemfuza ukuthintela ukubonakaliswa kwe-CD7, ukwenza inkqubo yemveliso ibe lula kwaye kuphuculwe ukusebenza konyango.
Olu phuhliso kwi-NS7CAR-T cell therapy luhambelana nemizamo eqhubekayo yokuphuhlisa unyango olusebenzayo ngakumbi lwe-T-ALL kunye ne-T-LBL. Inkampani yethu ikwaqhubela phambili kweli candelo ngeshishini lethu elikhethekileyo. Imveliso ye-CAR-T, esikholelwa ukuba iya kongeza kwiziphumo ezithembisayo ezibonwe ngonyango lwe-NS7CAR-T.
Iziphumo ezikhuthazayo zolu phononongo zivula indlela yophando olongezelelekileyo kunye novavanyo lweklinikhi ukuqinisa indima yeeseli ze-NS7CAR-T ekunyangeni ii-T-cell mollusks eziphinde zabuyela kwisimo sazo okanye ezingenakuchasana nazo. Njengoko ulwazi oluthe kratya lufumaneka, kunethemba lokuba olu nyango luza kuba lukhetho oluqhelekileyo kwizigulana ezilwa nezi zifo zinamandla.